Cellmid Ltd - Key Midkine Antibody Patents Granted in the US and Europe
Cellmid Ltd (ASX:CDY)

Key Midkine Antibody Patents Granted in the US and Europe


What's happened

Cellmid Ltd ("Cellmid") has received notice of allowance for its Improved midkine antibody patent from the United States Patent and Trademark Office (USPTO). Further to this, the European Patent Office (EPO) has also now issued a ‘Decision to Grant’ following a ‘Notification of Intention to Grant’ in 2019.

Why is this significant?

These midkine antibody patents are expected to help Cellmid in attracting potential commercial partners. Cellmid now have a dominant intellectual property position over the use of midkine therapeutic antibodies for the treatment of diseases arising from cancer, chronic inflammation, as well as functional disorders in T-regulatory cells and activated neutrophils associated with autoimmune diseases.

What does this announcement mean?

Erik Bergseng CFA® from Mawson Graham provides perspective on this recent announcement.
Erik Bergseng CFA®
Written by Erik Bergseng CFA®
Published Jan 06, 2020

As mentioned in the announcement it is expected that these new developments could help Cellmid with the commercialise of its midkine intellectual property via a potential partnership. This also follows the appointment of Mr. Bart Wuurman as the CEO of Lyramid who had previously negotiated a €600m option deal with Pfizer during his time as the CEO of AM-Pharma.

The information within this section has been provided by Mawson Graham Pty Ltd and is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information in this section has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained within this section to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham Pty Ltd, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham Pty Ltd, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, investor relations fees, corporate fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned within this section and in documents published within this section.
Mawson Graham
Mawson Graham

Download Announcement

View this announcement as well as our full profile on the company.

How do I invest?

Considering investing in Cellmid Ltd?
Here's how to get started.
Low Cost Brokerage ASX Cheapest ASX Trading Platform
  1. 1

    Create account

    Open an account with an online broker of your choice. If you do not have an existing broker, consider Mawson Graham's A$9.50 flat fee platform.

    Sign up now »
  2. 2

    Search for ASX:CDY

    On your online investment platform search for the stock ticker code ASX:CDY to bring up the company's shares.

  3. 3

    Buy shares

    Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.